# Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

> **NCT03995706** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 26 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT03995706
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-17
- **Primary completion:** 2022-06-03
- **Final completion:** 2024-03-20
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03995706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03995706, "Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03995706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*